Literature DB >> 19795368

Polypharmacy in primary care practices: an analysis using a large health insurance database.

Thomas Grimmsmann1, Wolfgang Himmel.   

Abstract

PURPOSE: To ascertain the rate and range of continuous polypharmacy in German general practices and compare practice characteristics and prescribing profiles in practices with a high rate of polypharmacy patients (HPP) and a low rate of polypharmacy patients (LPP), respectively.
METHODS: This observational study used a database composed of prescription data from a large German statutory health insurance. We defined polypharmacy as the continuous prescription of five or more drugs and calculated the percentage of polypharmacy patients for each practice to identify HPP and LPP.
RESULTS: A total of 136 521 patients in 730 general practices received continuous medication. About 10% of these patients (14 293/136 521) received five or more different drugs. HPP had, on average, 15.1% polypharmacy patients compared to 4.2% in LPP. The total number of patients attending either a HPP or LPP was comparable (437 vs. 416; p = 0.102), but HPP had a higher number of patients with prescriptions (76.9% vs. 70.8%; p < 0.0001). The patients' age distribution was similar (68.0 in LPP vs. 68.8 in HPP) and there were slightly more female patients in LPP. Doctors in HPP prescribed proton pump inhibitors and NSAIDs more frequently than doctors in LPP, but there was no difference in the prescription of me-too drugs.
CONCLUSION: The absolute differences in age and gender distribution between HPP and LPP were modest. Prescribing quality, as measured by the rate of me-too drug prescriptions, was similar across all practices. Therefore, differences in the rate of polypharmacy in general practice cannot sufficiently be explained by these factors. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19795368     DOI: 10.1002/pds.1841

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  16 in total

1.  Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy.

Authors:  S Lane Slabaugh; Vittorio Maio; Megan Templin; Safiya Abouzaid
Journal:  Drugs Aging       Date:  2010-12-01       Impact factor: 3.923

2.  Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-Elderly Project.

Authors:  Carlotta Franchi; Massimo Cartabia; Paolo Risso; Daniela Mari; Mauro Tettamanti; Alberto Parabiaghi; Luca Pasina; Codjo Djignefa Djade; Ida Fortino; Angela Bortolotti; Luca Merlino; Alessandro Nobili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-28       Impact factor: 2.953

3.  Polypharmacy and Renal Failure in Nursing Home Residents: Results of the Inappropriate Medication in Patients with Renal Insufficiency in Nursing Homes (IMREN) Study.

Authors:  Michael Dörks; Stefan Herget-Rosenthal; Guido Schmiemann; Falk Hoffmann
Journal:  Drugs Aging       Date:  2016-01       Impact factor: 3.923

4.  Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT.

Authors:  Catherine G Derington; Tyler H Gums; Adam P Bress; Jennifer S Herrick; Tom H Greene; Andrew E Moran; William S Weintraub; Ian M Kronish; Donald E Morisky; Katy E Trinkley; Joseph J Saseen; Kristi Reynolds; Jeffrey T Bates; Dan R Berlowitz; Tara I Chang; Michel Chonchol; William C Cushman; Capri G Foy; Charles T Herring; Lois Anne Katz; Marie Krousel-Wood; Nicholas M Pajewski; Leonardo Tamariz; Jordan B King
Journal:  Hypertension       Date:  2019-07-01       Impact factor: 10.190

5.  A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy.

Authors:  Yi-Ping Chang; San-Kuei Huang; Ping Tao; Ching-Wen Chien
Journal:  BMC Nephrol       Date:  2012-08-30       Impact factor: 2.388

6.  Prevalence and associated factors of polypharmacy among adult Saudi medical outpatients at a tertiary care center.

Authors:  Salih Bin Salih; Muhammad Yousuf; Huda Durihim; Hind Almodaimegh; Hani Tamim
Journal:  J Family Community Med       Date:  2013-09

7.  Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.

Authors:  Monira Alwhaibi; Bander Balkhi; Tariq M Alhawassi; Hadeel Alkofide; Nouf Alduhaim; Rawan Alabdulali; Hadeel Drweesh; Usha Sambamoorthi
Journal:  BMJ Open       Date:  2018-05-24       Impact factor: 2.692

8.  Prevalence and predictors of polypharmacy among Korean elderly.

Authors:  Hong-Ah Kim; Ju-Young Shin; Mi-Hee Kim; Byung-Joo Park
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

Review 9.  What is polypharmacy? A systematic review of definitions.

Authors:  Nashwa Masnoon; Sepehr Shakib; Lisa Kalisch-Ellett; Gillian E Caughey
Journal:  BMC Geriatr       Date:  2017-10-10       Impact factor: 4.070

10.  Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System.

Authors:  Renata Cristina Rezende Macedo do Nascimento; Juliana Álvares; Augusto Afonso Guerra; Isabel Cristina Gomes; Micheline Rosa Silveira; Ediná Alves Costa; Silvana Nair Leite; Karen Sarmento Costa; Orlando Mario Soeiro; Ione Aquemi Guibu; Margô Gomes de Oliveira Karnikowski; Francisco de Assis Acurcio
Journal:  Rev Saude Publica       Date:  2017-11-13       Impact factor: 2.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.